Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1One antithrombin binding sequence
What ifWhat if the dodecasaccharide carries a single antithrombin-binding pentasaccharide sequence?
Claim language“two AT-binding sequences”
A pentasaccharide containing a 3-O-sulfated glucosamine occupies five of the twelve residues. The pentasaccharide binds antithrombin and promotes factor Xa inhibition, while the seven flanking residues complete the chain.
1.1Propionyl at a terminal amine
What ifWhat if a terminal glucosamine amine at R1 or R3 carries a propionyl group?
Claim language“R1 and R3 are sulfo groups (—SO3H) or acetyl groups (—COCH3)”
An activated propionate ester acylates the exposed terminal glucosamine amine to form a propionamide. The amide caps the amine, and a separately positioned sulfated pentasaccharide provides the antithrombin-binding site.
1.2Phosphate on the hydroxyl
What ifWhat if the hydroxyl at R2 carries a phosphate ester?
Claim language“R2 is sulfo groups (—SO3H) or hydrogen (—H)”
A protected phosphate reagent reacts with the exposed hydroxyl during oligosaccharide assembly. Deprotection exposes an ionizable phosphate monoester that supplies local negative charge.
1.3Aliphatic tag for mass detection
What ifWhat if R4 is an aliphatic azidoalkyl group and mass spectrometry identifies the dodecasaccharide?
Claim language“phenyl or substituted phenyl group with characteristic UV absorption”
An azidoalkyl glycoside caps the reducing end. Liquid chromatography separates chain species, and negative-ion electrospray mass spectrometry identifies the target by its expected mass-to-charge values.
1.3Aliphatic tag for surface capture
What ifWhat if R4 is an aliphatic aminoalkyl group that anchors the dodecasaccharide to a sensor surface?
Claim language“aromatic heterocycle or substituted aromatic heterocycle”
A terminal primary amine reacts with an activated carboxyl group on the sensor surface to form an amide. The sensor measures antithrombin association and dissociation by monitoring the change in surface refractive index.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Activity reference for polysaccharide fractionation
A quality control laboratory uses the purified dodecasaccharide as a reference when profiling fractions from a heparin separation process. Separate wells contain serial dilutions of the reference and each fraction, with the same concentrations of antithrombin and factor Xa in all wells. Residual factor Xa cleaves a chromogenic substrate, and the reference dilution series provides a calibration curve for reporting the activity of each fraction.
Component substitution
Coumarin tag at the reducing end
A 4-methylumbelliferyl group replaces the para-nitrophenyl group at the reducing end of the dodecasaccharide. A glucosaminide bearing the coumarin group serves as the starting acceptor for chain extension, and subsequent sulfation establishes the two antithrombin-binding sequences. An absorbance detector monitors the coumarin chromophore during purification, and a factor Xa assay measures the activity of the isolated material.
Single-site glucuronic acid spacer
A β-D-glucuronic acid residue replaces one 2-O-sulfated iduronic acid residue at a position outside both antithrombin-binding sequences. The substitution preserves the 12-residue chain and its 1→4 glycosidic linkages while interrupting a potential run of trisulfated disaccharides. Stepwise assembly places glucuronic acid at that position, and tandem mass spectrometry checks the adjacent sulfation pattern.
Parameter or scale variation
Paired activity and neutralization titration
A 384-well plate holds an eight-point, twofold dilution series of the dodecasaccharide from 0.78 to 100 nM in 20 µL final volumes. Matched wells contain 0, 0.5, or 1.0 µg/mL protamine, with assay controls at each protamine concentration. After a five-minute preincubation with antithrombin and protamine, factor Xa and a chromogenic substrate are added, and the initial absorbance slopes quantify recovery of factor Xa activity.
Combination with existing systems
Inline monitoring of anion exchange fractions
A strong anion exchange column connects in series to an ultraviolet absorbance detector, a conductivity detector, and a fraction collector. A rising salt gradient elutes the sulfated dodecasaccharide, and the aromatic end group provides the absorbance signal used to start and stop fraction collection. The collected fractions are desalted and analyzed by mass spectrometry to identify material with the expected chain mass and sulfate count.
Automated or data-driven variant
Automated pairing of activity and composition
A liquid handler splits each purified fraction into paired aliquots for liquid chromatography–mass spectrometry and a plate-based factor Xa assay. Software associates the measured mass and candidate sulfate count with the initial substrate cleavage rate using the fraction identifier. The software flags fractions that meet defined mass and activity criteria and directs a repeat measurement when duplicate assay wells differ by more than 15% of their mean rate.
Specific version of a part
Two sulfated glucosamine amines
Sulfo groups occupy both R1 and R3 on the glucosamine amines. After deprotection, sodium counterions balance the negative charges of the resulting N-sulfate groups.
Sulfate ester at R2
Sulfation converts the exposed hydroxyl at R2 to an O-sulfate ester during assembly. Deprotection releases the remaining protected hydroxyl groups.
Para nitrophenyl end group
A para-nitrophenyl glycoside caps the reducing end through an anomeric oxygen linkage. Its aromatic chromophore supplies a UV signal for tracking tagged chain species during liquid chromatography.
Iduronic acid at G
A C5 epimerase converts a glucuronic acid precursor at G to iduronic acid by inverting the configuration at carbon 5. Nuclear magnetic resonance distinguishes the two uronic acid residues through their proton chemical shifts and coupling patterns.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1two AT-binding sequences and lacking consecutive multiple trisulfated disaccharide (IdoA2S-GlcNS6S) units, or pharmaceutically acceptable salts thereof, having the structure shown in formula I. wherein R1 and R3 are sulfo groups (—SO3H) or acetyl groups (—COCH3)
The carbon atom at position 6 of the D-glucosamine residues partially undergoes O-sulfation, and the amino group of D-glucosamine residues may undergo N-acetylation or N-sulfation.
A · US 2006/0293275 A1 · ¶ 9
The uronic acid unit may be sulfated in position 2 and the glucosamine unit is N-acetylated or N-sulfated and 6-O sulfated.
B · US 8,227,449 B2 · ¶ 8
1.2R2 is sulfo groups (—SO3H) or hydrogen (—H)
(a) formula (I): wherein R1 represents hydrogen, sulfate group, alkyl, acyl, or optionally substituted amino group, R2 represents hydrogen, sulfate group, alkyl or acyl group, R3 and R4are different from each other and represent hydrogen or optionally substituted carboxyl group, and n represents 0 to 7,
A · US 2006/0293275 A1 · ¶ 31
1.3R4 is selected from phenyl or substituted phenyl group with characteristic UV absorption, or aromatic heterocycle or substituted aromatic heterocycle
1.4sugar residue G is glucuronic acid (GlcA) or iduronic acid (IdoA) residue.
An uronic acid residue may be either an L-iduronic acid residue (hereinafter, abbreviated as IdoA) or a D-glucronic acid residue (hereinafter, abbreviated as GlcA).
A · US 2006/0293275 A1 · ¶ 77
In particular heparin, principally obtained by extraction from intestinal pig mucosa or bovine lung, is a mixture of chains consisting of repeating disaccharide units formed by an uronic acid (L-iduronic acid or D-glucuronic acid) and by an amino sugar (glucosamine), joined by α-1→4 or β-1→4 bonds.
B · US 8,227,449 B2 · ¶ 8
An empty cell means only that no passage was reproduced there.
Statements in these documents
The present invention relates to an agent for promoting HGF production comprising a sugar chain compound such as low-molecular-weight oligosaccharides having a heparin structure, or a salt thereof.
A · US 2006/0293275 A1 · ¶ 1
The present invention concerns new glycosaminoglycans derived from K5 polysaccharide which show all the biological characteristics of heparin of extractive origin, at a substantially similar or even higher extent.
B · US 8,227,449 B2 · ¶ 2
More generally, the invention provides a method for improving the C5-epimerization of the glucuronyl unit of an N-deacetylated N-sulfated K5 polysaccharide by carrying out said epimerization in the presence of at least one bivalent cation selected from the group consisting of barium, calcium, magnesium and manganese ions.
B · US 8,227,449 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0356990 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356990/, SHA-256 3ebb155e99fcf782770122151e9b89c2226a5c883d5ef04fd8efb69c0d96bad0